Minerva Neurosciences (NERV) Tops Q2 EPS by 12c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Minerva Neurosciences (NERV) Tops Q2 EPS by 12c

Minerva Neurosciences Reports Second Quarter 2016 Financial Results and Business Updates

August 4, 2016 7:30 AM EDT

Positive clinical data advance development with MIN-101 in schizophrenia and MIN-117 in major depressive disorder

Additional trials also planned with MIN-202 in insomnia disorder and major depressive disorder

WALTHAM, Mass., Aug. 04, 2016 (GLOBE NEWSWIRE) --  Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the quarter ended June 30, 2016.

Positive data announced during the second quarter of 2016 reinforced the differentiated product... More